Gene therapy tested as last hope for patients facing amputation
NCT ID NCT00696124
Summary
This early-stage study tested the safety of a new gene therapy called VM202 (Engensis) in 12 people with critical limb ischemia, a severe form of poor leg circulation causing pain and ulcers. The goal was to see if injections into the leg muscle were safe and if they might improve blood flow. Participants had no other treatment options and received two injections two weeks apart, with safety monitored for up to five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL LIMB ISCHEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital
Minneapolis, Minnesota, 55407, United States
Conditions
Explore the condition pages connected to this study.